The group’s principle activity is to develop novel protein-based therapeutics as anti-cancer agents. The group’s products include Evade(TM) RNase QBI-139,Targeted Evade(TM) Ribonucleases and Evade(TM) Ribonuclease Zymogen. The group operates from United States.